Research statistics

ATX-304 research: publications and trials

What has been published on ATX-304: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether ATX-304 works or is safe. For what it is and what the studies found, see the ATX-304 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

14

Since 2018

Publications in 2026 so far

1

Through November 15, 2026

Human clinical research

7.1%

1 of 14 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

0

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

92.9%

13 animal · 0 in vitro · 0 computational

Records that only mention it

2

Not counted above

Status in the library: In clinical trials. Groups: Longevity and mitochondrial peptides.

What to keep in mind

  • Fewer than three randomized controlled trials are indexed.
  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

ATX-304 publications by year and evidence

2018, Human clinical research: 1 of 12019, Preclinical (animal, in vitro, computational): 2 of 22021, Preclinical (animal, in vitro, computational): 2 of 22022, Preclinical (animal, in vitro, computational): 2 of 22023, Preclinical (animal, in vitro, computational): 2 of 22024, Preclinical (animal, in vitro, computational): 2 of 22025, Preclinical (animal, in vitro, computational): 2 of 22026 (to date), Preclinical (animal, in vitro, computational): 1 of 1Human clinical researchPreclinical (animal, in vitro, computational)0122018202120232026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Total
2018101
2019022
2021022
2022022
2023022
2024022
2025022
2026 (to date)011

Study types

Animal study13
Other clinical trial1

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health5
Cardiovascular4
Neurological and mental health4
Endocrinology3
Musculoskeletal3
Longevity and aging2
Cognitive health1
Gastrointestinal1
Obesity and weight management1
Reproductive and sexual health1
Tissue repair1

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.

    JCI insight · June 21, 2018 · Other clinical trial · cited 108 times · open access

    PMID 29925691 · DOI 10.1172/jci.insight.99114 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.

    JCI insight · June 21, 2018 · Other clinical trial · cited 108 times · open access

    PMID 29925691 · DOI 10.1172/jci.insight.99114 · Human clinical research

  2. NTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway.

    Cell death discovery · October 31, 2023 · Animal study · cited 41 times · open access

    PMID 37907480 · DOI 10.1038/s41420-023-01685-7 · Animal studies

  3. AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice.

    Communications biology · November 18, 2021 · Animal study · cited 27 times · open access

    PMID 34795407 · DOI 10.1038/s42003-021-02837-0 · Animal studies

  4. AMPK Activator O304 Protects Against Kidney Aging Through Promoting Energy Metabolism and Autophagy.

    Frontiers in pharmacology · March 2, 2022 · Animal study · cited 23 times · open access

    PMID 35308246 · DOI 10.3389/fphar.2022.836496 · Animal studies

  5. Antihyperalgesia effect of AMP-activated protein kinase (AMPK) activators in a mouse model of postoperative pain.

    Regional anesthesia and pain medicine · June 21, 2019 · Animal study · cited 15 times · open access

    PMID 31229963 · DOI 10.1136/rapm-2019-100651 · Animal studies

Latest publications

  1. Ginkgolide B mitigates doxorubicin-induced cardiotoxicity by regulating AMPK-mediated mitochondrial fission via P-Drp1/OPA1 and apoptosis.

    Archives of biochemistry and biophysics · August 20, 2026 · Animal study · cited 0 times

    PMID 42624274 · DOI 10.1016/j.abb.2026.110979 · Animal studies

  2. O304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries.

    Chemico-biological interactions · October 21, 2025 · Animal study · cited 2 times

    PMID 41130350 · DOI 10.1016/j.cbi.2025.111788 · Animal studies

  3. AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching.

    JCI insight · April 8, 2025 · Animal study · cited 12 times · open access

    PMID 40197369 · DOI 10.1172/jci.insight.179990 · Animal studies

  4. O304 alleviates abdominal aortic aneurysm formation via AMPK/mTOR/MMP pathway activation.

    Frontiers in pharmacology · November 29, 2024 · Animal study · cited 7 times · open access

    PMID 39679375 · DOI 10.3389/fphar.2024.1457817 · Animal studies

  5. The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · May 14, 2024 · Animal study · cited 9 times · open access

    PMID 38749175 · DOI 10.1016/j.biopha.2024.116730 · Animal studies

  6. NTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway.

    Cell death discovery · October 31, 2023 · Animal study · cited 41 times · open access

    PMID 37907480 · DOI 10.1038/s41420-023-01685-7 · Animal studies

  7. O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function.

    Communications biology · August 25, 2023 · Animal study · cited 8 times · open access

    PMID 37626210 · DOI 10.1038/s42003-023-05255-6 · Animal studies

  8. Analgesic Effectiveness and Dorsal Root Ganglia Protein Modulation of a Peripheral Adenosine Monophosphate Kinase Alpha Activator (O304) Following Lumbar Disk Puncture in the Mouse.

    Anesthesia and analgesia · October 6, 2022 · Animal study · cited 2 times

    PMID 36201356 · DOI 10.1213/ane.0000000000006228 · Animal studies

  9. AMPK Activator O304 Protects Against Kidney Aging Through Promoting Energy Metabolism and Autophagy.

    Frontiers in pharmacology · March 2, 2022 · Animal study · cited 23 times · open access

    PMID 35308246 · DOI 10.3389/fphar.2022.836496 · Animal studies

  10. Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice.

    Scientific reports · December 23, 2021 · Animal study · cited 12 times · open access

    PMID 34949756 · DOI 10.1038/s41598-021-03567-3 · Animal studies

Browse all 14 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: ATX-304; O304

((TITLE_ABS:"ATX-304" OR CHEM:"ATX-304" OR TITLE_ABS:"ATX304" OR CHEM:"ATX304") OR (TITLE_ABS:"O304" OR CHEM:"O304" OR TITLE_ABS:"O 304" OR CHEM:"O 304")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). ATX-304 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/atx-304